Section of Endocrine Surgery, Department of Surgery, University of Chicago Medicine, Chicago, IL.
Section of Endocrine Surgery, Department of Surgery, University of Chicago Medicine, Chicago, IL.
J Am Coll Surg. 2021 Jul;233(1):39-49. doi: 10.1016/j.jamcollsurg.2021.03.025. Epub 2021 Apr 19.
Current guidelines recommend total thyroidectomy (TT) and radioablation for most papillary thyroid cancer (PTC) in children. These guidelines have been criticized as aggressive, especially for early-stage PTC, as it likely does not influence patient survival and results in life-long thyroid hormone replacement. We sought to study whether the extent of thyroidectomy (TT vs thyroid lobectomy [TL]) influences overall and disease-specific survival in children with localized PTC.
The National Cancer Database and the Surveillance, Epidemiology, and End Results registries were queried. Patients 18 years or younger with low-risk PTC between 2004 and 2016 were included. Using a 1:1 propensity score matching, patients who underwent TT were matched for age, sex, race, year of diagnosis, and tumor size with a similar cohort of patients who underwent TL. Primary end points were overall survival and disease-specific survival.
There were 3,500 patients identified as surgically treated for PTC, of which 1,325 patients met inclusion criteria for matching. Three hundred and twenty-six patients were matched. One hundred and sixty-three patients had TT; 140 were female and mean age was 16 years (interquartile range [IQR] 13 to 17 years). One hundred and sixty-three patients had TL; 140 were female and mean age was 16 years (IQR 14 to 17 years). Median follow-up was 5.0 years (IQR 2.8 to 8 years) and 8.3 years (IQR 3.6 to 14.4 years) in the National Cancer Database and Surveillance, Epidemiology, and End Results cohorts, respectively. There was no statistically significant difference in overall survival or disease-specific survival in patients with PTC < 4 cm, regardless of whether patients underwent TT or TL (p = 0.32 for National Cancer Database registry and p = 0.67 for Surveillance, Epidemiology, and End Results registry).
This study suggests that the extent of thyroidectomy does not influence survival for pediatric patients with early-stage PTC and that TL might be adequate in this patient population.
目前的指南建议对大多数儿童甲状腺乳头状癌(PTC)患者进行甲状腺全切除术(TT)和放射性碘治疗。这些指南受到了批评,认为其过于激进,尤其是对于早期 PTC 患者,因为它可能不会影响患者的生存,且会导致终身甲状腺激素替代治疗。我们试图研究甲状腺切除术的范围(TT 与甲状腺叶切除术 [TL])是否会影响局限性 PTC 患儿的总生存率和疾病特异性生存率。
我们查询了国家癌症数据库和监测、流行病学和最终结果登记处。纳入了 2004 年至 2016 年间患有低危 PTC 且年龄在 18 岁或以下的患者。通过 1:1 倾向评分匹配,将接受 TT 的患者与接受 TL 的类似患者进行年龄、性别、种族、诊断年份和肿瘤大小匹配。主要终点为总生存率和疾病特异性生存率。
共发现 3500 例患者接受了 PTC 手术治疗,其中 1325 例符合匹配标准。对 326 例患者进行了匹配。163 例患者接受 TT,其中 140 例为女性,平均年龄为 16 岁(四分位距 [IQR] 13 至 17 岁)。163 例患者接受 TL,其中 140 例为女性,平均年龄为 16 岁(IQR 14 至 17 岁)。中位随访时间分别为国家癌症数据库队列中的 5.0 年(IQR 2.8 至 8 年)和监测、流行病学和最终结果队列中的 8.3 年(IQR 3.6 至 14.4 年)。在肿瘤<4cm 的 PTC 患者中,无论患者接受 TT 还是 TL,其总生存率或疾病特异性生存率均无统计学差异(国家癌症数据库登记处 p=0.32,监测、流行病学和最终结果登记处 p=0.67)。
本研究表明,甲状腺切除术的范围不会影响早期 PTC 患儿的生存,对于该患者群体,TL 可能已经足够。